<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642044</url>
  </required_header>
  <id_info>
    <org_study_id>005/07-CEP</org_study_id>
    <nct_id>NCT00642044</nct_id>
  </id_info>
  <brief_title>Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study</brief_title>
  <official_title>Corneal Collagen Crosslinking With Riboflavin for Keratoconus Treatment: A Brazilian Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-linking of the cornea increases the mechanical and biochemical stability of the stromal
      tissue. The purpose of this study is to assess the effectiveness of riboflavin-ultraviolet
      light induced cross-linking of corneal collagen in improving visual acuity and reducing
      progression of keratoconus in the Brazilian population.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Keratometry</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BSCVA (Best spectacle corrected visual acuity)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial cell count</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eye with the worst visual acuity receives the treatment. (the other eye serve as control).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The eye with the best visual acuity do not receive the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Corneal Collagen Crosslinking</intervention_name>
    <description>UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 35 years.

          -  Diagnosis of Keratoconus.

          -  Progression of Ametropia.

          -  Written informed consent.

        Exclusion Criteria:

          -  Corneal Thickness &lt; 395 micra at thinnest point.

          -  Other active ocular disease than keratectasia.

          -  Cornea Guttata.

          -  Previous ocular surgery.

          -  Pregnancy.

          -  Known sensitivity to riboflavin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Lamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Lamy, MD</last_name>
    <phone>55-21-2714-7646</phone>
    <email>lamy@ufrj.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clementino Fraga Filho University Hospital</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Lamy</last_name>
      <email>lamy@ufrj.br</email>
    </contact>
    <investigator>
      <last_name>Ricardo Lamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.hucff.ufrj.br</url>
    <description>Clementino Fraga Filho University Hospital</description>
  </link>
  <reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003 May;135(5):620-7.</citation>
    <PMID>12719068</PMID>
  </reference>
  <reference>
    <citation>Spoerl E, Huhle M, Seiler T. Induction of cross-links in corneal tissue. Exp Eye Res. 1998 Jan;66(1):97-103.</citation>
    <PMID>9533835</PMID>
  </reference>
  <reference>
    <citation>Kolozsv치ri L, N칩gr치di A, Hopp B, Bor Z. UV absorbance of the human cornea in the 240- to 400-nm range. Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2165-8.</citation>
    <PMID>12091412</PMID>
  </reference>
  <reference>
    <citation>Sekundo W, Stevens JD. Surgical treatment of keratoconus at the turn of the 20th century. J Refract Surg. 2001 Jan-Feb;17(1):69-73.</citation>
    <PMID>11201780</PMID>
  </reference>
  <reference>
    <citation>Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45.</citation>
    <PMID>16765803</PMID>
  </reference>
  <reference>
    <citation>Spoerl E, Mrochen M, Sliney D, Trokel S, Seiler T. Safety of UVA-riboflavin cross-linking of the cornea. Cornea. 2007 May;26(4):385-9. Review.</citation>
    <PMID>17457183</PMID>
  </reference>
  <reference>
    <citation>Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcine corneas after riboflavin-ultraviolet-A-induced cross-linking. J Cataract Refract Surg. 2003 Sep;29(9):1780-5.</citation>
    <PMID>14522301</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>April 22, 2008</last_update_submitted>
  <last_update_submitted_qc>April 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Adalmir Morter치 Dantas / Department of Ophthalmology Chief</name_title>
    <organization>UFRJ - Department of Ophthalmology</organization>
  </responsible_party>
  <keyword>Keratoconus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

